Skip to content
Screener

Perspective Therapeutics CATX Q1 2025 earnings

Reported May 12, 2025 · After market close

Revenue$342.0KBeat by $156.1K
EPS-$0.25Beat by $0.03
Revenue estimate$185.9K
EPS estimate-$0.28

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$62.1K
EPS estimate-$0.24

Financials

Q1 2025

Income statement

See full
Operating income-$21.8M-67.9%
Net income-$18.2M-48.0%
EPS (diluted)-$0.250.0%

Balance sheet

See full
Cash & equivalents$44.4M-68.8%
Total debt$3.8M+33.1%
Total equity$284.6M+23.8%
Total assets$329.3M+18.3%

Cash flow

See full
Operating cash flow-$21.6M-256%
CapEx$4.7M-48.7%
Free cash flow-$26.2M-649%

Valuation & ratios

Valuation

as of 03/30/25
See full
Market cap$157.73M-77.4%
Enterprise value$117.09M-79.1%

Returns & leverage

See full
Return on equity-33.1%-0.5pp
Debt / equity0×0.0×
Current ratio17×+4.0×

FAQ

When did Perspective Therapeutics report Q1 2025 earnings?
Perspective Therapeutics (CATX) reported Q1 2025 earnings on May 12, 2025 after market close.
What were Perspective Therapeutics's Q1 2025 revenue and EPS?
Perspective Therapeutics reported revenue of $342.0K and eps of $-0.25 for Q1 2025.
Did Perspective Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $185.9K by $156.1K. EPS beat the consensus estimate of $-0.28 by $0.03.
How did Perspective Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 5.2% from $325.0K a year earlier and eps declined 25.0% from $-0.20.
Where can I find Perspective Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-069301) and the 10-Q periodic report (0000950170-25-069314) directly on SEC EDGAR. The filing index links above go to sec.gov.